Format

Send to

Choose Destination
See comment in PubMed Commons below
AJP Rep. 2013 Oct;3(2):71-4. doi: 10.1055/s-0033-1338169. Epub 2013 Mar 18.

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy.

Author information

1
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, MedStar Health, Washington, District of Columbia.

Abstract

Background Pulmonary arterial hypertension carries a high risk of mortality in pregnancy. Recent advances in treatment may improve disease course and allow for successful management of the pregnancy. Case Report We present the case of a 20-year-old gravida 1, para 0 with diagnosis of severe primary pulmonary hypertension. The patient was managed with epoprostenol (prostacyclin) infusion via an indwelling catheter, which was initiated at 23 weeks' gestation. The dose was adjusted to the patient's symptoms and a successful vaginal delivery was achieved at 36 weeks' gestation. Although maternal postpartum course was uncomplicated, unexplained neonatal demise occurred at 11 days of life. Conclusion Successful management of pulmonary hypertension in pregnancy can be accomplished with a multidisciplinary approach and intensive therapy. Long-term effects of epoprostenol on fetal or neonatal well-being are unknown.

KEYWORDS:

epoprostenol; prostacyclin; prostaglandin; pulmonary hypertension

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York Icon for PubMed Central
    Loading ...
    Support Center